Theravance Biopharma (TBPH) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $329.7 million.
- Theravance Biopharma's Cash & Current Investments rose 26085.42% to $329.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.7 million, marking a year-over-year increase of 26085.42%. This contributed to the annual value of $88.4 million for FY2024, which is 1374.26% down from last year.
- According to the latest figures from Q3 2025, Theravance Biopharma's Cash & Current Investments is $329.7 million, which was up 26085.42% from $338.8 million recorded in Q2 2025.
- Theravance Biopharma's Cash & Current Investments' 5-year high stood at $486.8 million during Q3 2022, with a 5-year trough of $88.4 million in Q4 2024.
- In the last 5 years, Theravance Biopharma's Cash & Current Investments had a median value of $167.5 million in 2023 and averaged $198.9 million.
- In the last 5 years, Theravance Biopharma's Cash & Current Investments plummeted by 7247.45% in 2023 and then soared by 26085.42% in 2025.
- Quarter analysis of 5 years shows Theravance Biopharma's Cash & Current Investments stood at $173.5 million in 2021, then skyrocketed by 88.79% to $327.5 million in 2022, then crashed by 68.72% to $102.4 million in 2023, then dropped by 13.74% to $88.4 million in 2024, then surged by 273.15% to $329.7 million in 2025.
- Its Cash & Current Investments stands at $329.7 million for Q3 2025, versus $338.8 million for Q2 2025 and $130.9 million for Q1 2025.